Dr. Sarah Moran is an Assistant Professor of Nephrology, Clinician Scientist and Nephrologist at Queen’s University, Canada. Dr. Moran is a 2007 first class honours graduate of University College Cork School of Medicine. She received the Intern of the Year award at Cork University Hospital in 2008. She undertook basic and higher specialist training in Nephrology and Internal Medicine with the Royal College of Physicians of Ireland. As part of her training she was awarded a prestigious placement on the Health Research Board of Ireland National Specialist Registrar Academic Fellowship Programme in 2014. She then completed sub speciality fellowships in Glomerulonephritis and Obstetric Nephrology at the University of Toronto with the support of the Louise A. Fast Foundation scholarship. This was consolidated with further research training at the University of Toronto with support from the Ainsworth Scholarship and Postgraduate Travelling Scholarship in Medicine.
She is a passionate believer in the importance of quality improvement and patient safety and is a dedicated patient advocate. She has partnered with patient advocacy groups including Nephcure, Vasculitis Ireland and Vasculitis UK. She co-founded the Rare Kidney Diseases Registry and Biobank based at Trinity College Dublin which is now one of the largest vasculitis biobanks in the world and is a founding member of and former coordinator of the Vasculitis Ireland Network (VINE), a collaborative multidisciplinary group focused on the care of patients with systemic vasculitides. She is the South Eastern Ontario member of the Ontario Renal Network provincial pregnancy priority panel driving strategies to optimize care of these complex patients.
Dr. Moran’s research focuses on the development of novel urinary biomarkers of renal inflammation and fibrosis. Her PhD thesis has personalized patient care at its core. It focused on usCD163, a novel urinary biomarker of crescentic glomerulonephritis. This has been successfully translated its use from a laboratory research test to a clinically useful biomarker using prospective clinical studies and external validation with international collaborations. In collaboration with Euroimmun, a diagnostic grade usCD163 is now available. Her research has resulted in numerous peer-reviewed publications, grants and awards.